Because somatostatin analogue sensitizes tumor cells to mTOR inhibition and can also reverse resistance to mTOR inhibition through its inhibition of Akt [19,20], we expect that the combination of pasireotide long-acting release (LAR) and everolimus will result in even greater antitumor efficacy. This evidence concerns the gene MTOR and neoplasm.